Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposomes plus capecitabine chemoradiotherapy as neoadjuvant treatment for locally advanced rectal adenocarcinoma
ChiCTR2500109401Phase 2Not yet recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan and capecitabine in rectal adenocarcinoma, sponsored by Tianjin People's Hospital. Primary endpoint: Clinical benefit rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecancapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500109401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109401.